Resolution Bioscience, now a part of Agilent ctDx, is a leading brand in the field of cancer diagnostics. They specialize in providing comprehensive liquid biopsy assays using next-generation sequencing (NGS) and standard peripheral blood samples. Their innovative ctDx platform has been validated to detect all four major types of genetic alterations that drive cancers: SNVs, Indels, Fusions, and CNVs.

What sets Resolution Bioscience apart is their quick turnaround time, with results available in days rather than weeks. The brand's commitment to advancing cancer diagnostics is evident through their numerous breakthroughs and collaborations. They have partnered with leading pharmaceutical companies to support clinical trials and biomarker discovery, while also collaborating with clinicians to provide critical information for patient care.

Resolution Bioscience's dedication to helping patients is at the heart of their mission. By offering comprehensive tests and monitoring tumor evolution over time, they aim to provide the best diagnostics available. With their focus on accuracy, efficiency, and clinical utility, Resolution Bioscience is shaping the future of cancer diagnostics